en · de · es · fr · pt
cjc-1295-notes.peptides6908.com › Data › Mechanism And Pharmacokinetics — Questions and Answers

Mechanism And Pharmacokinetics — Questions and Answers

By Editorial Desk · published 2026-02-06 · last reviewed 2026-03-02 · Data

GHRH analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2026-03-02. Numbers and descriptions here follow the published literature rather than marketing material.

Mechanism and Pharmacokinetics

The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.

Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.

Background and Naming Conventions

Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.

CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.

The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.

Cjc-1295 at a glance

PropertyValueNotes
Target receptorGHRH receptor (GHRHR)Expressed on pituitary somatotrophs
Primary actionStimulates growth hormone releaseAmplifies pulse size
Half-life, albumin-binding formSeveral days as reportedSlow release from albumin complex
Half-life, unmodified analogAbout 30 minutes in animal estimatesCleared by proteases and filtration
Common analytical approachLC-MS/MS for peptide, immunoassay for hormonesMethods answer different questions

Background and Molecular Design

CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.

Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.

Related pages on this site

Background and Molecular Features

The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.

CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.

Supporting material

=== Acquired desmosis === The atrophic form is more frequent. Inflammation of the muscularis propria releases enzymes including collagenases which destroy the connective tissue of the bowel wall. Primarily newborns and small children are affected, although this manifestation can also be found in adults. The most common location is the colon with a necrotizing enterocolitis as well as Crohn Disease and diverticulitis. If the taenia are also affected, the disease is defined as complete atrophic desmosis, all other forms without involvement of the taenia are referred to as incomplete. Clinically, patients demonstrate chronic constipation.

=== Neuromuscular fatigue === Nerves control the contraction of muscles by determining the number, sequence, and force of muscular contraction. When a nerve experiences synaptic fatigue it becomes unable to stimulate the muscle that it innervates. Most movements require a force far below what a muscle could potentially generate, and barring pathology, neuromuscular fatigue is seldom an issue. For extremely powerful contractions that are close to the upper limit of a muscle's ability to generate force, neuromuscular fatigue can become a limiting factor in untrained individuals. In novice strength trainers, the muscle's ability to generate force is most strongly limited by nerve's ability to sustain a high-frequency signal. After an extended period of maximum contraction, the nerve's signal reduces in frequency and the force generated by the contraction diminishes. There is no sensation of pain or discomfort; instead, the muscle appears to simply "stop listening." and gradually cease to move, often lengthening. As there is insufficient stress on the muscles and tendons, there will often be no delayed onset muscle soreness following the workout. Part of the process of strength training is increasing the nerve's ability to generate sustained, high frequency signals which allow a muscle to contract with their greatest force. It is this "neural training" that causes several weeks worth of rapid gains in strength, which level off once the nerve is generating maximum contractions and the muscle reaches its physiological limit.

== Notable people == Avior Byron (born 1973), singer, songwriter, and musicologist Omri Casspi (born 1988), Israeli professional NBA basketball player Itai Chammah (born 1985), Olympic swimmer Gil Dor, guitar player Elishay Kadir (born 1987), basketball player Uri Kokia (born 1981), basketball player and coach Shlomi Koriat (born 1976), actor and comedian Maor Melikson, footballer Nevo Mizrahi (born 1987), footballer Mushail Mushailov, artist Ido Nehoshtan, Major-General (ret.), former chief of Israeli Air Force Shabak Samech, rap and hip-hop group Meir Sheetrit (born 1948), Israeli Minister of the Interior

Particular kinds of aquaculture include fish farming, shrimp farming, oyster farming, mariculture, pisciculture, algaculture (such as seaweed farming), and the cultivation of ornamental fish. Particular methods include aquaponics and integrated multi-trophic aquaculture, both of which integrate fish farming and aquatic plant farming. The FAO describes aquaculture as one of the industries most directly affected by climate change and its impacts. Some forms of aquaculture have negative impacts on the environment, such as through nutrient pollution or disease transfer to wild populations.

== Signs and symptoms == Common symptoms of obstructive sleep disorder syndrome include unexplained daytime sleepiness, restless sleep, frequent awakenings and loud snoring (with periods of silence followed by gasps). Less common symptoms are morning headaches; insomnia; trouble concentrating; mood changes such as irritability, anxiety, and depression; bruxism (teeth grinding), forgetfulness; increased heart rate or blood pressure; erectile dysfunction, unexplained weight gain; increased urinary frequency or nocturia; frequent heartburn or gastroesophageal reflux; and heavy night sweats. Many people experience episodes of OSA transiently, for only a short period. This can be the result of an upper respiratory infection that causes nasal congestion, swelling of the throat, or tonsillitis that temporarily produces very enlarged tonsils. The Epstein-Barr virus, for example, is known to be able to increase the size of lymphoid tissue dramatically during acute infection, and OSA is fairly common in acute cases of severe infectious mononucleosis. Temporary spells of OSA syndrome may also occur in people who are under the influence of a drug (such as alcohol) that may relax their body tone excessively and interfere with normal arousal from sleep mechanisms.

Sources: en.wikipedia.org

Supporting material

Congenital contractural arachnodactyly, also known as Beals–Hecht syndrome Ehlers–Danlos syndrome Homocystinuria Loeys–Dietz syndrome MASS phenotype Multiple endocrine neoplasia, type 2B Shprintzen–Goldberg syndrome Stickler syndrome

== Life and work == Lundsgaard was born in Copenhagen where his father was a physician who came from the Gundelach family of lawyers and civil servants His father received a gold medal for his work on prostatic hypertrophy from the University of Copenhagen. At school he played guitar as a hobby. In 1917 he completed school and entered medical studies. He completed studies in 1923 and worked at the institute of medical physiology under Valdemar Henriques. He received a doctorate in 1929. His major finding was on muscle contraction when glycolysis was blocked by mono-iodoacetate. He found that energy was drawn from the phosphate bond energy and he published the findings in 1930. Until then it was believed that glycolysis was the main source of energy. Creatine phosphate was independently identified in muscle by the Eggletons and by Cyrus H. Fiske and Subbarow in 1926. From 1934 he began to work on phlorizin and its metabolic effects. This was continued with insulin in studies of perfused livers. In 1938 he examined the metabolism of alcohol and its conversion to acetic acid by the liver. He received the Thunberg medal in 1960 and the Anders Jahre prize for 1964. Herman Kalckar was among his students. He retired in 1967 and died from renal cancer the next year.

This allowed for two Soviet Republics, Ukraine and Byelorussia, (as well as the USSR as a whole) to join the United Nations General Assembly as founding members in 1945. The Soviet currency Soviet ruble banknotes all included writings in national languages of all the 15 union republics. All of the former Republics of the Union are now independent countries, with ten of them (all except the Baltic states, Georgia and Ukraine) being very loosely organized under the heading of the Commonwealth of Independent States. The Baltic states assert that their incorporation into the Soviet Union in 1940 (as the Lithuanian, Latvian, and Estonian SSRs) under the provisions of the 1939 Molotov–Ribbentrop Pact was illegal, and that they therefore remained independent countries under Soviet occupation. Their position is supported by the European Union, the European Court of Human Rights, the United Nations Human Rights Council and the United States. In contrast, the Russian government and state officials maintain that the Soviet annexation of the Baltic states was legitimate.

In February 2015, the FDA reported about a transmission risk when people undergo a gastroenterology procedure called endoscopic retrograde cholangiopancreatography, where an endoscope enters the mouth, passes the stomach, and ends in the duodenum; if incompletely disinfected, the device can transmit CRE from one patient to another. The FDA's safety communication came a day after the UCLA Health System, Los Angeles, notified more than 100 patients that they may have been infected with CRE during endoscopies between October 2014 and January 2015. The FDA had issued its first notice about the devices in 2009.

Sources: en.wikipedia.org

Frequently asked questions

How long does the albumin-binding form remain active?

Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.

What do researchers measure after administering the peptide?

Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.

Are the clinical effects well established?

Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.

Does this compound occur naturally in the body?

No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.

Network